Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Debt Ratio (2022 - 2025)

Taysha Gene Therapies' Debt Ratio history spans 4 years, with the latest figure at 0.16 for Q3 2025.

  • For Q3 2025, Debt Ratio fell 32.63% year-over-year to 0.16; the TTM value through Sep 2025 reached 0.16, down 32.63%, while the annual FY2024 figure was 0.27, 16.84% up from the prior year.
  • Debt Ratio for Q3 2025 was 0.16 at Taysha Gene Therapies, up from 0.12 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.91 in Q3 2023 and bottomed at 0.12 in Q2 2025.
  • The 4-year median for Debt Ratio is 0.26 (2024), against an average of 0.31.
  • The largest annual shift saw Debt Ratio skyrocketed 169.95% in 2023 before it plummeted 73.93% in 2024.
  • A 4-year view of Debt Ratio shows it stood at 0.3 in 2022, then fell by 22.0% to 0.23 in 2023, then rose by 16.84% to 0.27 in 2024, then tumbled by 41.37% to 0.16 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Debt Ratio are 0.16 (Q3 2025), 0.12 (Q2 2025), and 0.31 (Q1 2025).